财务表现 - The Cooper Companies在2024年1月结束的季度报告显示，营收达到9.316亿美元，同比增长8.5% [1] - 每股收益为0.85美元，较去年同期的0.73美元有所增长 [1] - 公司的营收超出了Zacks Consensus Estimate的915.17亿美元，增幅为+1.80% [2] - 每股收益也超出了预期，为0.85美元，增幅为+7.59% [2] 地区营收表现 - 美洲地区营收为2.526亿美元，略低于分析师平均预期的2.5299亿美元 [5] - 亚太地区营收为1.307亿美元，低于三位分析师平均预期的1.3782亿美元 [6] - 欧洲、中东和非洲地区营收为2.382亿美元，高于三位分析师平均预期的2.2571亿美元 [7] 产品类别营收表现 - CVI类别营收为6.215亿美元，高于七位分析师平均预期的6.1499亿美元，同比增长6.9% [8] - CSI类别营收为3.101亿美元，高于七位分析师平均预期的3.0103亿美元，同比增长11.9% [9] - CSI-生育类别营收为1.19亿美元，略低于六位分析师平均预期的1.2122亿美元，同比增长6.3% [10] - CSI-办公和手术类别营收为1.911亿美元，高于六位分析师平均预期的1.7982亿美元，同比增长15.7% [11] 股票表现 - The Cooper Companies股票在过去一个月中表现为+1.3%，略低于Zacks S&P 500综合指数的+3.9% [12]

The Cooper Companies (COO) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.59%. A quarter ago, it was expected that this surgical and contact lens products maker would post earnings of $0.87 per share when it actually produced earnings of $0.87, delivering no surprise.Over the last ...

财务状况 - CooperVision在2024年1月31日的三个月内，Toric and multifocal镜片销售额为297.3百万美元，同比增长14%[67] - CooperVision在2024年1月31日的三个月内，Sphere, other镜片销售额为324.2百万美元，同比增长1%[67] - CooperVision在2024年1月31日的三个月内，外部产品在净销售额中占比约为1%[69] - 公司的整体毛利率在2024年1月31日结束的三个月内增加到了67%，相比于2023年1月31日结束的三个月的65%，主要是由于效率提升和价格上涨[76] - 2024年1月31日和2023年10月31日的营运资金分别为8.29亿美元和7.359亿美元[90] 经营活动 - 2024年1月31日的经营活动现金流为1.227亿美元，较2023年1月31日的1.666亿美元有所下降[91] - 2024年前三个月的投资活动现金流增加，主要是因为收购Cook Medical支付了2亿美元[92] - 2024年前三个月的融资活动现金流主要是因为借款2亿美元用于支付Cook Medical的收购[93] 风险管理 - 公司暴露于主要与利率变动和外汇波动相关的市场风险[104] - 公司暴露于外汇风险，10%的外汇汇率变动将导致运营收入增减约2990万美元[106]

PRESS RELEASE CooperCompanies Announces First Quarter 2024 Results San Ramon, Calif., February 29, 2024 — CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2024. • Revenue increased 9% year-over-year to $931.6 million. CooperVision (CVI) revenue up 7% to $621.5 million, and CooperSurgical (CSI) revenue up 12% to $310.1 million. • GAAP diluted earnings per share (EPS) of $0.41, down $0.02 or 5% from last ye ...

The Cooper Companies, Inc.’s (COO) first-quarter fiscal 2024 results are scheduled to be released on Feb 29, after the closing bell.In the last reported quarter, the company’s earnings were in line with the Zacks Consensus Estimate. Its earnings beat estimates in two of the trailing four quarters and met twice, delivering an average surprise of 2.84%.Q1 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $915.2 million for the soon-to-be-reported quarter, indicating a 6.6% increase from the year ...

The Cooper Companies (COO) - The Cooper Companies (COO)将在2024年1月结束的季度公布财报，预计盈利将同比增长，市场普遍预期公司的收入将增加[1] - 如果公司的实际业绩超过预期，股价可能会上涨；反之，如果未达预期，股价可能会下跌[2] - 分析师们对公司的季度盈利预期进行了修订，预计每股收益为0.79美元，同比增长8.2%，营收预计为9.1517亿美元，同比增长6.6%[4] - 分析师们最近对公司的盈利前景变得悲观，导致预期盈利与实际盈利之间的差距为-0.99%，但公司目前持有Zacks Rank 3[12] - 过去四个季度中，The Cooper Companies两次超过了分析师的盈利预期[15] - 公司的Earnings ESP为-0.99%，这意味着很难确定The Cooper Companies是否会超过市场预期[12] Merit Medical (MMSI) - Merit Medical (MMSI)预计将在2024年1月结束的季度公布财报，预计每股收益为0.77美元，同比下降2.5%，营收预计为3.1903亿美元，同比增长8.7%[19] - Merit Medical的盈利预期已经被修订，现在具有0.43%的Earnings ESP，结合Zacks Rank 3 (Hold)，预计公司将超过市场预期[20]

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Labcorp (LH) or The Cooper Companies (COO) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with st ...

文章核心观点 - 公司宣布将于2024年2月16日下午5点生效的4:1股票拆分 [1][2] - 股票拆分旨在使公司股票更易于员工和投资者购买 [1] - 公司之前在2023年第四季度财报中宣布了此次股票拆分计划 [2] - 拆分后公司普通股的新CUSIP编号为216648501 [2] 公司概况 - CooperCompanies是一家领先的全球医疗器械公司,专注于通过两大业务部门CooperVision和CooperSurgical改善人们的生活 [3][4] - CooperVision是接触镜行业的领导者,每天改善数百万人的视力 [4] - CooperSurgical是一家领先的生育和妇女健康公司,致力于在最关键的时刻为女性、婴儿和家庭提供帮助 [4] - 公司总部位于加州圣拉蒙,拥有超过15,000名员工,产品销往130多个国家 [4]

The Cooper Companies’ (COO) wholly-owned subsidiary CooperSurgical and Fulgent Genetics recently announced their partnership to provide exclusive newborn genetic screening panels to Cord Blood Registry (CBR) families.As a result of this collaboration, CBR by CooperSurgical brand will offer families a variety of genetic testing choices by utilizing Fulgent's Picture Genetics platform.Price PerformanceFor the past six months, COO’s shares have lost 0.3% compared with the industry’s decline of 2.3%. The S&P 50 ...

Cooper Companies, Inc.业务展望 - Cooper Companies, Inc. (COO)在其CooperVision (CVI)和CooperSurgical (CSI)业务部门拥有强劲的增长前景[1] - CVI部门在最近一个季度表现强劲，收入以恒定汇率和有机基础上涨11%至6.229亿美元[7] - CSI部门的收入预计在2024财年将增长4-6%[10] - 公司的2024财年收入预期为38.5亿美元，较2023年报告数字增长7.2%[13]